COMP <GO>
TMCI vs ABBV // FORWARD P/E MULTIPLE
Treace Medical Concepts Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: TMCI 1
— ABBV 10
■ METRIC PARITY
LAST: $4.43 (-12.45%) • MKT CAP: $329.1M
forward-pe
—
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TMCI VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TMCI | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.80% | 70.20% | +9.60 | TMCI | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.40% | 29.00% | -61.40 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.96% | 3.47% | -12.43 | ABBV | /fcf-yield <GO> |
| Operating Margin | -25.50% | 24.60% | -50.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -27.70% | 6.90% | -34.60 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 1.60% | 8.60% | -7.00 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.90 | 5.33 | -4.43 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.7 | 65.1 | -2.40 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $329.1M | $513.86B | -$513.53B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TMCI REV | ABBV REV | TMCI GROSS % | ABBV GROSS % | TMCI FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $212.7M | $61.16B | 79.8% | 70.2% | -$29.5M | $17.82B |
| FY 2024 | $209.4M | $56.33B | 80.4% | 70.0% | -$48.8M | $17.83B |
| FY 2023 | $187.1M | $54.32B | — | — | -$34.6M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TMCI // BETA —
ABBV // BETA 1.15